http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-114156-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_96b882006e755dfc56fcabfc5fb019f6 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D491-048 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D491-10 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4525 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D491-10 |
| filingDate | 2018-12-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2020-07-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-114156-A1 |
| titleOfInvention | B-3 ADRENERGIC RECEPTOR MODULATORS USEFUL FOR THE TREATMENT OR PREVENTION OF DISORDERS RELATED TO THIS |
| abstract | The present refers to compounds of formula (1) and to pharmaceutical compositions of these that modulate the activity of the adrenergic receptor b-3. The compounds herein and the pharmaceutical compositions thereof relate to methods useful for treating a b-3 adrenergic receptor mediated disorder, such as heart failure; cardiac output in heart failure; mortality, reinfarction and / or hospitalization related to heart failure; acute heart failure; acute decompensated heart failure; congestive heart failure; severe congestive heart failure; damage to an organ associated with heart failure; heart failure due to left ventricular dysfunction; heart failure with normal ejection fraction; cardiovascular mortality after myocardial infarction; cardiovascular mortality in patients with left ventricular failure or left ventricular dysfunction; left ventricular failure; left ventricular dysfunction; class II heart failure; class III heart failure; class IV heart failure; LVEF <40% according to radionuclide ventriculography; LVEF & Claim 1: A compound selected from the compounds of formula (1) and pharmaceutically acceptable salts, solvates, hydrates and N-oxides thereof, wherein: X is -SO₂- or is absent; R¹ is selected from: aryl, C₁₋₆ alkylene-aryl, C₁₋₆ alkylene-heteroaryl, C₃₋₇ cycloalkyl, heteroaryl, and heterocyclyl; each optionally substituted with one or more substituents selected from: C₁₋₆ alkoxy, C₁₋₆ alkoxycarbonyl, C₁₋₇ alkyl, C₁₋₆ alkylamino, C₁₋₆ alkylcarboxamide, C₁₋₆ alkylsulfonamido, C₁₋₆ alkylsulfonyl, amino, aryloxy , arylsulfonyl, carboxamide, carbamimidoyl, carboxy, cyano, C₃₋₇ cycloalkyl, C₂₋₈ dialkylamino, C₂₋₈ dialkylsulfamoyl, C₁₋₆ haloalkoxy, C₁₋₆ haloalkyl, halogen, heterocyclyl, hydroxycarbamimidoyl, hydroxyl, oxo, and sulfamoyl; and wherein said C₁₋₆ alkoxy, C₁₋₇ alkyl, C₁₋₆ alkylamino, aryloxy, C₃₋₇ cycloalkyl and C₂₋₈ dialkylamino are each optionally substituted with one or more substituents selected from: amino, C₁₋₆ alkoxy, C₁₋₆ alkylamino, C₁₋₆ alkylcarboxamide, carboxy, Y-C₁₋₆-Z alkylene optionally substituted with oxo, C₃₋₇ cycloalkyl, cyano, C₂₋₆ dialkylamino, C₁₋₆ haloalkyl, C₁₋₆ haloalkylamino, heterocyclyl, hydroxyl , oxo and phenyl; Y is selected from: -O- and -NH-; Z is selected from: C₁₋₆ alkoxy, amino, C₁₋₆ alkylamino, cyano, C₂₋₆ dialkylamino, hydroxyl, and phenyl; R²ᵃ is H or is selected from: C₁₋₆ alkoxy, C₁₋₆ alkyl, C₃₋₇ cycloalkyl, and heterocyclyl; each optionally substituted with one or more substituents selected from: C₁₋₆ alkoxy, C₁₋₆ alkylamino, C₁₋₆ alkyl, C₁₋₆ alkylene hydroxy, amino, C₃₋₇ cycloalkyl, cyano, C₂₋₈ dialkylamino, optionally substituted heterocyclyl an oxo, halogen, hydroxyl and oxo group; and R²ᵇ is H or C₁₋₆ alkyl. |
| priorityDate | 2017-12-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 24.